San Francisco, Calif., April 2, 2014 – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision-making in molecular medicine, and The Jackson Laboratory (JAX), an independent, nonprofit biomedical research institution with a staff of over 1,500 employees, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
The partnership with JAX represents CollabRx’s first such relationship with a large and influential non-profit biomedical research institute and demonstrates the company’s accelerating pace of business and channel development in 2014. This new milestone attests to the growing adoption of CollabRx technology and interpretive analytics in top-tier laboratories worldwide as a standard aspect of test reporting for clinical genetic sequencing in cancer and other diseases.
“The Jackson Laboratory, now in its 85th year, has pioneered the use of genomics and bioinformatics to advance cancer research by bridging basic biology and translational studies to accelerate the development of new therapies,” said Thomas Mika, Chairman, President & CEO of CollabRx. “We are excited and proud to work with the Laboratory, an NCI-designated Cancer Center, to provide physicians with a clinically relevant interpretation of genetic sequencing test results as a seamless part of the reporting process.”
Under the terms of the agreement, CollabRx medical and scientific knowledge will be incorporated into the results of genetic sequencing-based tests in oncology provided by JAX. JAX will leverage CollabRx’s dynamically updated knowledgebase in molecular medicine, ensuring that the latest medical and scientific data is made available to ordering physicians to aid in their interpretation of test results and inform patient-treatment planning. CollabRx’s knowledgebase includes the clinical impact of specific genetic profiles and is supported by its large and growing network of over 75 leading clinical practitioners in the United States and Europe.
The partnership will leverage each organization’s commitment to developing cutting-edge medical informatics solutions to integrate, automate and standardize molecular testing and reporting in oncology. These capabilities are vital to the large-scale molecular analysis of tumors using clinical genetic sequencing, given the sheer volume and complexity of genetic data that is produced. While genetic sequencing-based tests are increasingly becoming an important part of the clinical management of cancer patients, the resulting explosion of data has outpaced the ability of practicing physicians to understand how to apply this genetic data in treating their patients.
“A contextualized interpretation of cancer mutation panels is critical in using a genomics-based approach to inform cancer-treatment planning,” said Dr. Charles Lee, Director of the Jackson Laboratory for Genomic Medicine, in Farmington, CT. “CollabRx has developed a scalable process and software platform to provide a best-in-class medical informatics solution that will enable JAX to arm physicians with a meaningful analysis of a tumor’s molecular characteristics when determining a cancer-treatment plan.”
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
About The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution and National Cancer Institute-designated Cancer Center based in Bar Harbor, Maine, with a facility in Sacramento, Calif., and a new genomic medicine institute in Farmington, Conn. It employs a total staff of more than 1,500. Its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. More information may be obtained at http://www.jax.org/.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Gavin J. Gordon, MBA, PhD
Vice President of Business Development & Strategic Alliances
Business Manager, Clinical Genomics and Genetic Services